Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy: a population-bas ed study in six Europe anregions

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy : a population-bas ed study in six Europe anregions. / Charlton, Ra; Jordan, S; Pierini, A; Garne, Ester; Neville, Aj; Hansen, Av; Gini, R; Thayer, D; Tingay, K; Puccini, A; Bos, Hj; Andersen, Anne-Marie Nybo; Sinclair, M; Dolk, H; de Jong-van den Berg, Ltw.

In: B J O G, Vol. 122, No. 7, 2015, p. 1010-1020.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Charlton, R, Jordan, S, Pierini, A, Garne, E, Neville, A, Hansen, A, Gini, R, Thayer, D, Tingay, K, Puccini, A, Bos, H, Andersen, A-MN, Sinclair, M, Dolk, H & de Jong-van den Berg, L 2015, 'Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy: a population-bas ed study in six Europe anregions', B J O G, vol. 122, no. 7, pp. 1010-1020. https://doi.org/10.1111/1471-0528.13143

APA

Charlton, R., Jordan, S., Pierini, A., Garne, E., Neville, A., Hansen, A., ... de Jong-van den Berg, L. (2015). Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy: a population-bas ed study in six Europe anregions. B J O G, 122(7), 1010-1020. https://doi.org/10.1111/1471-0528.13143

Vancouver

Charlton R, Jordan S, Pierini A, Garne E, Neville A, Hansen A et al. Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy: a population-bas ed study in six Europe anregions. B J O G. 2015;122(7):1010-1020. https://doi.org/10.1111/1471-0528.13143

Author

Charlton, Ra ; Jordan, S ; Pierini, A ; Garne, Ester ; Neville, Aj ; Hansen, Av ; Gini, R ; Thayer, D ; Tingay, K ; Puccini, A ; Bos, Hj ; Andersen, Anne-Marie Nybo ; Sinclair, M ; Dolk, H ; de Jong-van den Berg, Ltw. / Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy : a population-bas ed study in six Europe anregions. In: B J O G. 2015 ; Vol. 122, No. 7. pp. 1010-1020.

Bibtex

@article{b607e3b0b1e848f688ffd420ac8fce9b,
title = "Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy: a population-bas ed study in six Europe anregions",
abstract = "OBJECTIVE: To explore the prescribing patterns of selective serotonin reuptake inhibitors (SSRIs) before, during and after pregnancy in six European population-based databases.DESIGN: Descriptive drug utilisation study.SETTING: Six electronic healthcare databases in Denmark, the Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest of the UK.POPULATION: All women with a pregnancy ending in a live or stillbirth starting and ending between 2004 and 2010.METHODS: A common protocol was implemented across databases to identify SSRI prescriptions issued (UK) or dispensed (non-UK) in the year before, during or in the year following pregnancy.MAIN OUTCOME MEASURES: The percentage of deliveries in which the woman received an SSRI prescription in the year before, during or in the year following pregnancy. We also compared the choice of SSRIs and changes in prescribing over the study period.RESULTS: In total, 721 632 women and 862 943 deliveries were identified. In the year preceding pregnancy, the prevalence of SSRI prescribing was highest in Wales [9.6{\%}; 95{\%} confidence interval (CI95 ), 9.4-9.8{\%}] and lowest in Emilia Romagna (3.3{\%}; CI95 , 3.2-3.4{\%}). During pregnancy, SSRI prescribing had dropped to between 1.2{\%} (CI95 , 1.1-1.3{\%}) in Emilia Romagna and 4.5{\%} (CI95 , 4.3-4.6{\%}) in Wales. The higher UK pre-pregnancy prescribing rates resulted in higher first trimester exposures. After pregnancy, SSRI prescribing increased most rapidly in the UK. Paroxetine was more commonly prescribed in the Netherlands and Italian regions than in Denmark and the UK.CONCLUSIONS: The higher SSRI prescribing rates in the UK, compared with other European regions, raise questions about differences in the prevalence and severity of depression and its management in pregnancy across Europe.",
author = "Ra Charlton and S Jordan and A Pierini and Ester Garne and Aj Neville and Av Hansen and R Gini and D Thayer and K Tingay and A Puccini and Hj Bos and Andersen, {Anne-Marie Nybo} and M Sinclair and H Dolk and {de Jong-van den Berg}, Ltw",
note = "{\circledC} 2014 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.",
year = "2015",
doi = "10.1111/1471-0528.13143",
language = "English",
volume = "122",
pages = "1010--1020",
journal = "B J O G",
issn = "1470-0328",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Selective serotonin reuptake inhibitorprescribing before, during and after pregnancy

T2 - a population-bas ed study in six Europe anregions

AU - Charlton, Ra

AU - Jordan, S

AU - Pierini, A

AU - Garne, Ester

AU - Neville, Aj

AU - Hansen, Av

AU - Gini, R

AU - Thayer, D

AU - Tingay, K

AU - Puccini, A

AU - Bos, Hj

AU - Andersen, Anne-Marie Nybo

AU - Sinclair, M

AU - Dolk, H

AU - de Jong-van den Berg, Ltw

N1 - © 2014 The Authors. BJOG An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

PY - 2015

Y1 - 2015

N2 - OBJECTIVE: To explore the prescribing patterns of selective serotonin reuptake inhibitors (SSRIs) before, during and after pregnancy in six European population-based databases.DESIGN: Descriptive drug utilisation study.SETTING: Six electronic healthcare databases in Denmark, the Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest of the UK.POPULATION: All women with a pregnancy ending in a live or stillbirth starting and ending between 2004 and 2010.METHODS: A common protocol was implemented across databases to identify SSRI prescriptions issued (UK) or dispensed (non-UK) in the year before, during or in the year following pregnancy.MAIN OUTCOME MEASURES: The percentage of deliveries in which the woman received an SSRI prescription in the year before, during or in the year following pregnancy. We also compared the choice of SSRIs and changes in prescribing over the study period.RESULTS: In total, 721 632 women and 862 943 deliveries were identified. In the year preceding pregnancy, the prevalence of SSRI prescribing was highest in Wales [9.6%; 95% confidence interval (CI95 ), 9.4-9.8%] and lowest in Emilia Romagna (3.3%; CI95 , 3.2-3.4%). During pregnancy, SSRI prescribing had dropped to between 1.2% (CI95 , 1.1-1.3%) in Emilia Romagna and 4.5% (CI95 , 4.3-4.6%) in Wales. The higher UK pre-pregnancy prescribing rates resulted in higher first trimester exposures. After pregnancy, SSRI prescribing increased most rapidly in the UK. Paroxetine was more commonly prescribed in the Netherlands and Italian regions than in Denmark and the UK.CONCLUSIONS: The higher SSRI prescribing rates in the UK, compared with other European regions, raise questions about differences in the prevalence and severity of depression and its management in pregnancy across Europe.

AB - OBJECTIVE: To explore the prescribing patterns of selective serotonin reuptake inhibitors (SSRIs) before, during and after pregnancy in six European population-based databases.DESIGN: Descriptive drug utilisation study.SETTING: Six electronic healthcare databases in Denmark, the Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest of the UK.POPULATION: All women with a pregnancy ending in a live or stillbirth starting and ending between 2004 and 2010.METHODS: A common protocol was implemented across databases to identify SSRI prescriptions issued (UK) or dispensed (non-UK) in the year before, during or in the year following pregnancy.MAIN OUTCOME MEASURES: The percentage of deliveries in which the woman received an SSRI prescription in the year before, during or in the year following pregnancy. We also compared the choice of SSRIs and changes in prescribing over the study period.RESULTS: In total, 721 632 women and 862 943 deliveries were identified. In the year preceding pregnancy, the prevalence of SSRI prescribing was highest in Wales [9.6%; 95% confidence interval (CI95 ), 9.4-9.8%] and lowest in Emilia Romagna (3.3%; CI95 , 3.2-3.4%). During pregnancy, SSRI prescribing had dropped to between 1.2% (CI95 , 1.1-1.3%) in Emilia Romagna and 4.5% (CI95 , 4.3-4.6%) in Wales. The higher UK pre-pregnancy prescribing rates resulted in higher first trimester exposures. After pregnancy, SSRI prescribing increased most rapidly in the UK. Paroxetine was more commonly prescribed in the Netherlands and Italian regions than in Denmark and the UK.CONCLUSIONS: The higher SSRI prescribing rates in the UK, compared with other European regions, raise questions about differences in the prevalence and severity of depression and its management in pregnancy across Europe.

U2 - 10.1111/1471-0528.13143

DO - 10.1111/1471-0528.13143

M3 - Journal article

C2 - 25352424

VL - 122

SP - 1010

EP - 1020

JO - B J O G

JF - B J O G

SN - 1470-0328

IS - 7

ER -

ID: 135533462